Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRIDE · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| STRIDE (durvalumab + tremelimumab) | ACTIVE_COMPARATOR | - |
| STRIDE (durvalumab + tremelimumab) + Lenvatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRIDE (durvalumab + tremelimumab) | DRUG | As first treatment |
| Durvalumab | DRUG | monotherapy every 4 weeks |
| Lenvatinib | DRUG | Daily |
Inclusion Criteria: * Age ≥ 18 years. * Body weight \> 30 kg. * Life expectancy of at least 12 weeks. * Confirmed HCC based on histopathological findings from tumour tissues or clinically by AASLD criteria in cirrhotic participants. * Must not have received prior systemic therapy for HCC. * Must no...
STRIDE is a combination of durvalumab and tremelimumab being studied for the treatment of unresectable hepatocellular carcinoma. It is currently in Phase 2 clinical development as an investigational therapy. The combination is being evaluated in a randomized, active-controlled trial to assess its efficacy and safety in this patient population.
STRIDE is a combination of two immunotherapies: durvalumab, a PD-L1 inhibitor, and tremelimumab, a CTLA-4 inhibitor. These agents work by blocking immune checkpoint pathways, which may enhance the body's immune response against cancer cells. The combination is being investigated for its potential to improve outcomes in hepatocellular carcinoma.
STRIDE is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the safety and efficacy of the durvalumab plus tremelimumab combination in patients with unresectable hepatocellular carcinoma.
STRIDE is currently in Phase 2 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting patients to evaluate the combination of durvalumab and tremelimumab with or without lenvatinib in unresectable hepatocellular carcinoma.
STRIDE is being evaluated in a Phase 2 clinical trial with the identifier NCT06880523. This randomized, active-controlled study is recruiting 140 patients with unresectable hepatocellular carcinoma in Canada. The trial compares STRIDE (durvalumab plus tremelimumab) with lenvatinib versus STRIDE alone, and is open to adults aged 18 years and older.
Yes, STRIDE is the name given to the combination of durvalumab and tremelimumab. This combination is being studied as a potential treatment for unresectable hepatocellular carcinoma. The ongoing clinical trial evaluates STRIDE both alone and in combination with lenvatinib to determine the most effective treatment approach.